首页> Hematological oncology> A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma.

A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma.

导出原文传递

翻译打印收藏纠错

第一作者： Serena,Rocchi

第一单位： Azienda Ospedaliero-Universitaria di Bologna, Italia - Istituto di Ematologia "Seràgnoli", Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale - Università degli Studi, Bologna, Italy.

作者： Serena,Rocchi ^[1] ; Paola,Tacchetti ^[1] ; Lucia,Pantani ^[1] ; Katia,Mancuso ^[1] ; Ilaria,Rizzello ^[1] ; Chiara,di Giovanni Bezzi ^[1] ; Marco,Scalese ^[2] ; Luca,Dozza ^[1] ; Giulia,Marzocchi ^[1] ; Marina,Martello ^[1] ; Gregorio,Barilà ^[3] ; Elisabetta,Antonioli ^[4] ; Michela,Staderini ^[4] ; Gabriele,Buda ^[5] ; Mario,Petrini ^[5] ; Michele,Cea ^[6] ; Micol,Quaresima ^[7] ; Anna,Furlan ^[8] ; Angela,Bonalumi ^[9] ; Michele,Cavo ^[1] ; Elena,Zamagni ^[1]

作者单位： Azienda Ospedaliero-Universitaria di Bologna, Italia - Istituto di Ematologia "Seràgnoli", Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale - Università degli Studi, Bologna, Italy. ^[1] Teseo Srl, Pisa, Italy. ^[2] Hematology and Clinical Immunology, Padua University School of Medicine, Padua, Italy. ^[3] Haematology Unit, Careggi University Hospital, Florence, Italy. ^[4] Department of Clinical and Experimental Medicine, U.O. Hematology, University of Pisa, Pisa, Italy. ^[5] Hematology Unit, Department of Internal Medicine (DiMI), University of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. ^[6] Hematology Unit, AUSL-IRCSS, Reggio Emilia, Italy. ^[7] U.O. Hematology, Ca Foncello Hospital, Treviso, Italy. ^[8] Hematology Unit, Department of Medicine, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. ^[9]

关键词 carfilzomib-lenalidomide-dexamethasone efficacy multiple myeloma real-life relapse safety